


Direct C–H Alkenylation of Functionalized Pyrazoles

Su Jin Han, Hyun Tae Kim, and Jung Min Joo*

Department of Chemistry and Chemistry Institute of Functional Materials, Pusan National University, Busan 46241, Republic of Korea

S Supporting Information

ABSTRACT: We have developed inter- and intramolecular C–H alkenylation reactions of pyrazoles. The catalyst, derived from Pd(OAc)₂ and pyridine, enabled the oxidative alkenylation of pyrazoles containing a variety of functional groups at the C4 position. Activated alkenes, including acrylate, acrylamide, and styrene derivatives, and enamides could be installed in this process. The sequential C–H alkenylation and cyclization reactions gave rise to fused bicyclic pyrazoles, providing a new strategy to annulate readily available pyrazole compounds.



Direct C–H functionalization reactions of heteroarenes have been established as an alternative to traditional cross-coupling reactions, allowing for rapid preparation of complex heteroarenes for investigation in biological applications and functional materials.¹ Pyrazoles represent one of the most sought-after heterocycles for C–H functionalization reactions due to their importance in medicinal chemistry, agrochemical science, and organometallic chemistry.² For efficient synthesis of the pyrazole library, a C–H functionalization strategy is even more appealing because of the instability and high cost of prefunctionalized pyrazole building blocks.³ Many new methods have been developed for the direct substitution of C–H bonds on the pyrazole ring, with a particular focus on arylation.⁴ One strategy to promote arylation of pyrazoles utilizes electron-withdrawing groups to activate the C–H bond of the pyrazole ring.⁵ Additionally, we have demonstrated that not only the acidity of the C–H bond but also the Lewis basicity of the nitrogen atom can be modulated by electron-withdrawing groups, thus preventing *N*-alkylation with alkyl halides and enabling catalytic C–H alkylation reactions of pyrazoles.⁶

In contrast to arylation and alkylation reactions, the installation of alkenyl groups onto the pyrazole ring has had limited success.^{7–9} Consistent with low regioselectivity in the arylation of unsubstituted pyrazoles, an alkenylation reaction of 1-methylpyrazole gave a mixture of regioisomers (Figure 1A).^{4a,8b} Furthermore, the Lewis basic nitrogen atom serves as a directing group for C–H functionalization at the neighboring arene ring, rather than the pyrazole ring (Figure 1B).¹⁰ Lewis basicity was also attributed to the failure of pyrazole alkenylation using a directing group strategy that was successful in the regioselective C–H alkenylation of indoles.¹¹ While we addressed the issues of regioselectivity and high Lewis basicity of pyrazoles in C–H alkylation by taking advantage of electron-withdrawing groups, we observed that the efficiency of the catalytic system, derived from Pd(OAc)₂ and PPh₃,




Figure 1. (A) Reactivity of an unsubstituted pyrazole in alkenylation. (B) Pyrazoles as a directing group in the alkenylation of arenes. (C) Dehydrogenative alkenylation of functionalized pyrazoles and subsequent cyclization to give fused bicyclic pyrazoles.

considerably decreased as the electron-withdrawing ability of the substituent decreased from nitro to carbonyl to chloride.^{6b} In order to expand the scope of C–H functionalization of pyrazoles by overcoming the limitations arising from phosphine-ligated Pd complexes, we investigated a phosphine-free system to facilitate C–H metalation of pyrazoles having a wide range of electronic properties.¹² Specifically, we envisioned a catalytic cycle that involved palladation of pyrazoles prior to the generation of an aryl or alkyl palladium species, thus expanding the classes of coupling partners beyond aryl and alkyl halides. We have demonstrated the feasibility of


Received: October 15, 2015

Published: December 23, 2015

the alternative catalytic cycle by developing the dehydrogenative Heck reaction of pyrazoles (Figure 1C). In this process, pyrazoles possessing a functional group at the C4 position, including nitro, carbonyl, halo, alkyl, and aryl groups, can be subjected to C5-selective olefination reactions.¹⁵ Subsequently, these alkenylation products can undergo interconversion of the functional groups or cyclization between the preinstalled functional groups and the newly introduced alkenes to produce fused pyrazole bicycles that are otherwise difficult to obtain.¹⁴ Herein, we report the oxidative C–H alkenylation of functionalized pyrazoles. A variety of alkenyl groups can be incorporated in an intermolecular or intramolecular fashion, and the subsequent cyclization of the alkene products provides fused bicyclic pyrazoles.

We first examined the alkenylation reaction of 1-methyl-4-nitropyrazole (1a) with different oxidants, which revealed that Cu(OAc)₂ was superior to silver-based oxidants (Table 1,

Table 1. Alkenylation of 1-Methyl-4-nitropyrazole^a



entry	additive	oxidant	yield (%) ^b		
			2a	3a	4a
1	–	Ag ₂ CO ₃	15	0	0
2	–	AgOAc	30	3	3
3	–	Cu(OAc) ₂	47	6	6
4 ^c	2,2'-bipyridine	Cu(OAc) ₂	–	–	–
5 ^c	1,10-phenanthroline	Cu(OAc) ₂	–	–	–
6	pyridine	Cu(OAc) ₂	62	7	7
7 ^c	pyridine	Cu(OAc) ₂	57	8	8
8	pyridine	Cu(OAc) ₂ ·H ₂ O	65	8	7
9 ^d	pyridine	Cu(OAc) ₂	66	8	5
10	pyridine	O ₂	15	2	1
11	pyridine	air	7	–	–


^aReaction conditions: pyrazole (0.50 mmol), butyl acrylate (0.50 mmol), Pd(OAc)₂ (0.050 mmol), additive (0.10 mmol), oxidant (1.0 mmol), 1,4-dioxane (0.50 M), 120 °C. ^b¹H NMR yield. ^cThe amount of additive was reduced to 10 mol %. ^dThe reaction was carried out with 0.50 equiv of Cu(OAc)₂ in an open flask.

entries 1–3). Bidentate nitrogen ligands, added as ancillary ligands, only inhibited the catalytic reaction (entries 4 and 5).¹⁵ Based on the mechanistic study of C–H alkenylation, pyridine was tested as a monodentate nitrogen ligand that can readily undergo ligand exchange, resulting in an improved reaction yield (entry 6).¹⁶ This result showed that pyridine was a more competent ligand in oxidative alkenylation than the pyrazole substrate. A comparable result was obtained when 10 mol % of pyridine was used instead of 20 mol %, indicating that the ratio of Pd/pyridine was not critical in pyrazole alkenylation (entry 7).¹⁷ The hydrated form of Cu(OAc)₂ was employed in place of the anhydrous counterpart without affecting the reaction yield (entry 8). While the amount of the copper salt could be reduced to 50 mol % when the reaction was conducted in an open flask (entry 9), microscale reactions to examine the substrate scope were performed with 2 equiv of Cu(OAc)₂.

H₂O due to the convenience of the experimental setup. The copper salt was a necessary inclusion; in the absence of Cu(OAc)₂, air and oxygen were insufficient to reoxidize the Pd catalyst (entries 10 and 11). In the screening experiments, we observed small amounts of the (Z)-isomer and dialkenylation products, 3a and 4a, respectively, the latter of which offered the opportunity for application to the C3-alkenylation of indazoles using this protocol (*vide infra*).

The optimized conditions were applied to a variety of readily available olefins (Table 2). Butyl and ethyl acrylates gave 2a-c

Table 2. Alkene Substrate Scope^a



^aReaction conditions: pyrazole (0.50 mmol), alkene (0.50 mmol), Pd(OAc)₂ (0.050 mmol), pyridine (0.10 mmol), Cu(OAc)₂·H₂O (1.0 mmol), 1,4-dioxane (0.50 M), 120 °C. ^bYield of a 1-g-scale reaction. ^cThe reaction was performed in the absence of pyridine.

in good yields. The reaction of butyl methacrylate gave rise to the corresponding olefin isomerization product 2d.¹⁸ N,N-Diethylacrylamide worked equally well to furnish 2e in 67% yield. Styrene derivatives were also successfully coupled with the pyrazole ring (2f–h). Interestingly, an electron-rich alkene, 1-vinyl-2-pyrrolidinone, gave the corresponding alkenylation product 2i in 43% yield. However, an aliphatic olefin, 3,3-dimethylbut-1-ene, was not amenable to this process (2j).

As anticipated from the reactivity of the Pd/pyridine system, pyrazoles substituted with a broad range of functional groups underwent C–H olefination (Table 3). The common pyrazole protecting group, 2-(trimethylsilyl)ethoxymethyl (SEM) group, was tolerated (entries 1, 6, 9, and 10), whereas protecting groups able to chelate with palladium in cooperation with the pyrazole nitrogen, such as THP and Me₂NSO₂ groups, were unsuitable for this protocol (results not shown). Carbonyl groups, including ester and ketone functionalities (entries 2–4), could be used, and it is notable that reasonable yields of 7b and 7c were obtained despite the presence of acidic α-protons in the acetyl group. Furthermore, chloro and bromo groups on the pyrazole ring were tolerated, providing opportunities for further synthetic elaboration of the resulting products (entries 5–9).¹⁹ Most importantly, alkyl and aryl pyrazoles, represented as 13a and 14a, respectively, underwent alkenylation reactions under the same reaction conditions as optimized for electron-deficient pyrazoles (entries 10 and 11).²⁰ The alkenylation of (2H)-indazole 15a could also be performed without additional

Table 3. Pyrazole Substrate Scope^a

entry	reactant	product	yield	entry	reactant	product	yield
1			74%	8			57%
2			51%	9			41%
3			43%	10			69%
4			49%	11			53%
5			67%	12			64%
6			64%	13			72%
7			55%	14			42%

^aReaction conditions: pyrazole (0.50 mmol), alkene (0.50 mmol), Pd(OAc)₂ (0.050 mmol), pyridine (0.10 mmol), Cu(OAc)₂·H₂O (1.0 mmol), 1,4-dioxane (0.50 M), 120 °C.

optimization (entries 12 and 13). Just as the C3 position of pyrazoles was vulnerable to C–H alkenylation, the C3 position of (1*H*)-indazole **16a** was alkenylated in this method (entry 14).

Both intermolecular alkenylation and the intramolecular variant could be carried out with pyrazole heterocycles (Table 4). Five-, six-, and seven-membered rings were readily constructed by Pd/Cu catalysis. In the reactions with pendant styryl groups (entries 1–3), the major products were *exo*-(*E*)-alkenes: the structures of **17b** and **19b** were confirmed by X-ray crystallographic analysis (see Supporting Information).²¹ Presumably, syn-addition of the palladated pyrazole followed by syn-β-hydride elimination was responsible for the stereochemical outcome, similar to other Heck-type reactions.²² The formation of the exocyclic alkenes represents a rare example of intramolecular alkenylation with a styryl group. In addition, nonactivated olefins could be used to prepare six- and seven-membered rings, as exemplified in the formation of **20b** and **21b**, respectively (entries 4 and 5).

In order to demonstrate the utility of the C–H alkenylation of pyrazoles in complex pyrazole synthesis, we pursued the

preparation of fused pyrazole rings from the resultant alkenylation products. A modified protocol for the Cadogan reaction was readily applied to the synthesis of pyrrolopyrazoles **22** and **23** from alkenyl nitropyrazoles **2a** and **2f**, respectively (Scheme 1).²³ In addition, the corresponding cyclopentapyrazolidene was generated by palladium-catalyzed annulation with an internal alkyne, favoring formation of the (*Z*)-isomer (**24**).²⁴


In conclusion, we have developed a new approach to prepare C5-alkenylated pyrazoles. The catalyst, derived from Pd(OAc)₂ and pyridine, in combination with Cu(OAc)₂·H₂O oxidant, enabled inter- and intramolecular alkenylation reactions of electronically varied pyrazoles, as well as indazoles. No special directing groups were required, but directing groups that were able to accompany the Lewis basic nitrogen atom of pyrazole to form a bidentate ligand had an inhibitory effect. Lewis basicity of pyrazoles was not detrimental to olefination. In fact, the addition of pyridine, a better Lewis base than pyrazole, was advantageous to oxidative alkenylation. Many synthetically versatile functional groups were tolerated in this process, including nitro, ester, ketone, chloro, bromo, methyl, and

Table 4. Intramolecular C–H Alkenylation of Pyrazoles

entry	reactant	product	yield
1			17b (47%)
2			18b (56%)
3			19b (56%)
4			20b (45%) ^a
5			21b (58%)

^aObtained as a mixture of the alkenylation product and the corresponding olefin isomerization product (6:1).

Scheme 1. Synthesis of Fused Pyrazoles from Alkenylation Products



phenyl groups in the pyrazole ring, and acrylates, acrylamides, styrenes, and an enamide in the olefin. Preinstalled functional groups at the pyrazole C4 position allowed for efficient alkenylation of pyrazoles and led to the formation of fused pyrazole bicycles that were challenging to access with conventional methods. The construction of fused pyrazole rings by the sequential addition of functional groups and alkenyl moieties to the parent pyrazole ring shows potential for the development of new strategies for pyrazole annulation, which are currently underway in our laboratory.

EXPERIMENTAL SECTION

Flash column chromatography was performed on silica gel (40–63 μm) using the indicated solvent system. NMR spectra were recorded in CDCl_3 at 300 K on a 300 MHz Fourier transform NMR spectrometer. Proton chemical shifts are expressed in parts per million

(ppm, δ scale) and are referenced to residual protium in the NMR solvent (CDCl_3 , δ 7.26). Carbon chemical shifts are expressed in parts per million (ppm, δ scale) and are referenced to the carbon resonance of the NMR solvent (CDCl_3 , δ 77.16). Infrared (IR) spectra are reported as absorption wavenumbers (cm^{-1}). High-resolution mass spectra (HRMS) were acquired on high-resolution mass spectrometers: Q-TOF (ionization mode: ESI) and magnetic sector–electric sector double focusing mass analyzer (ionization mode: EI).

General Procedure for C–H Alkenylation of Pyrazoles. To a solution of the pyrazole substrate (0.50 mmol) and 1,4-dioxane (1.0 mL, 0.50 M) in an 8 mL glass vial were added the alkene (0.50 mmol), $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ (200 mg, 1.0 mmol), pyridine (8.1 μL , 0.10 mmol), and $\text{Pd}(\text{OAc})_2$ (11 mg, 0.050 mmol). The reaction mixture was stirred at 120 °C for 12 h, then cooled to 25 °C, and concentrated. The residue was then purified by flash column chromatography to furnish the desired product.

1-Methyl-4-nitro-1H-pyrazole (1a).^{5d} To a stirred solution of 4-nitro-1H-pyrazole (3.00 g, 26.5 mmol) in DMF (15.0 mL) at 25 °C were added K_2CO_3 (4.40 g, 31.8 mmol) and iodomethane (1.98 mL, 31.8 mmol). After stirring for 14 h at 25 °C, the reaction mixture was treated with water (20 mL) and EtOAc (20 mL) and transferred to a 125 mL separatory funnel. The organic layer was collected and the aqueous layer was extracted with EtOAc (20 mL \times 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate and filtered. The filtrate was concentrated, and the residue was purified by flash column chromatography (hexanes/EtOAc = 1:3) to provide pyrazole 1a as a white solid (3.30 g, 98% yield). ^1H NMR (300 MHz, CDCl_3) δ 8.12 (s, 1H), 8.06 (s, 1H), 3.97 (s, 3H).

(E)-Butyl 3-(1-methyl-4-nitro-1H-pyrazol-5-yl)acrylate (2a). Purification by flash column chromatography (hexanes/EtOAc = 9:2) provided alkenylated pyrazole 2a as a yellow oil (78 mg, 62% yield). A 1-g-scale reaction was conducted with 1a (1.00 g, 7.90 mmol), *n*-butyl acrylate (1.13 mL, 7.90 mmol), $\text{Cu}(\text{OAc})_2$ (727 mg, 4.00 mmol), pyridine (129 μL , 1.60 mmol), $\text{Pd}(\text{OAc})_2$ (177 mg, 0.790 mmol), and 1,4-dioxane (10.0 mL, 0.790 M) in an open flask to give 2a (1.24 g, 62%). IR (film) 3127, 2958, 2874, 1714, 1651, 1538, 1393 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 8.14 (s, 1H), 7.89 (d, J = 16.5 Hz, 1H), 6.67 (d, J = 16.5 Hz, 1H), 4.26 (t, J = 6.7 Hz, 2H), 4.02 (s, 3H), 1.77–1.65 (m, 2H), 1.50–1.37 (m, 2H), 0.97 (t, J = 7.3 Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 165.3, 136.5, 135.3, 134.0, 128.5, 127.4, 65.4, 39.6, 30.6, 19.1, 13.7; HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{16}\text{N}_3\text{O}_4$ [$M + \text{H}$]⁺ 254.1135, found 254.1137.

(Z)-Butyl 3-(1-Methyl-4-nitro-1H-pyrazol-5-yl)acrylate (3a). Yellow oil. IR (film) 2960, 2874, 1723, 1501, 1402, 1318 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 8.10 (s, 1H), 6.98 (d, J = 11.8 Hz, 1H), 6.45 (d, J = 11.9 Hz, 1H), 4.08 (t, J = 6.7 Hz, 2H), 3.77 (s, 3H), 1.61–1.50 (m, 2H), 1.35–1.26 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 164.2, 136.6, 135.8, 129.0, 128.5, 110.1, 65.3, 38.2, 30.5, 19.1, 13.8; HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{16}\text{N}_3\text{O}_4$ [$M + \text{H}$]⁺ 254.1135, found 254.1145.

(2E,2'E)-Dibutyl 3,3'-(1-Methyl-4-nitro-1H-pyrazole-3,5-diyl)diacrylate (4a). Yellow solid. Mp 74–76 °C; IR (film) 2961, 2934, 2874, 1717, 1547, 1455, 1360 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 8.07 (d, J = 16.2 Hz, 1H), 7.88 (d, J = 16.0 Hz, 1H), 6.83 (d, J = 15.9 Hz, 1H), 6.53 (d, J = 15.9 Hz, 1H), 4.32–4.18 (m, 4H), 4.02 (s, 3H), 1.76–1.66 (m, 4H), 1.50–1.37 (m, 4H), 1.02–0.92 (m, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 166.2, 165.1, 142.5, 137.2, 131.5, 131.2, 128.7, 128.0, 124.5, 65.6, 64.9, 40.0, 30.7, 30.6, 19.3, 19.2, 13.8, 13.8; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{26}\text{N}_3\text{O}_6$ [$M + \text{H}$]⁺ 380.1816, found 380.1813.

(E)-Ethyl 3-(1-methyl-4-nitro-1H-pyrazol-5-yl)acrylate (2b). The ^1H NMR of the reaction mixture showed the formation of the corresponding (*E*)- and (*Z*)-olefination products and dialkenylation product (63%, 7%, and 5%, respectively). Purification by flash column chromatography (hexanes/EtOAc = 3:1) provided alkenylated pyrazole 2b as a yellow oil (72 mg, 64% yield). IR (film) 3128, 2984, 1717, 1650, 1538, 1503 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 8.14 (s, 1H), 7.89 (d, J = 16.5 Hz, 1H), 6.67 (d, J = 16.5 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 4.02 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 165.2, 136.5, 135.3, 133.9, 128.5, 127.4, 61.5,

39.6, 14.2; HRMS (ESI) calcd for $C_9H_{12}N_3O_4$ $[M + H]^+$ 226.0822, found 226.0827.

(E)-tert-Butyl 3-(1-Methyl-4-nitro-1H-pyrazol-5-yl)acrylate (2c). The 1H NMR of the reaction mixture showed the formation of the corresponding (E)- and (Z)-olefination products and dialkenylation product (64%, 9%, and 7%, respectively). Purification by flash column chromatography (hexanes/EtOAc = 9:2) provided alkenylated pyrazole 2c as a yellow solid (74 mg, 58% yield). Mp 64–66 °C; IR (film) 3129, 2980, 2932, 1714, 1645, 1505, 1370 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 8.14 (s, 1H), 7.80 (d, J = 16.5 Hz, 1H), 6.59 (d, J = 16.5 Hz, 1H), 4.01 (s, 3H), 1.55 (s, 9H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 164.4, 136.5, 135.6, 133.9, 130.4, 126.5, 82.1, 39.6, 28.1; HRMS (ESI) calcd for $C_{11}H_{16}N_3O_4$ $[M + H]^+$ 254.1135, found 254.1137.

Butyl 2-(1-(1-Methyl-4-nitro-1H-pyrazol-5-yl)methyl)acrylate (2d). Purification by flash column chromatography (hexanes/EtOAc = 5:1) provided alkenylated pyrazole 2d as a yellow oil (62 mg, 46% yield). IR (film) 2960, 2931, 2874, 1716, 1552, 1427 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 8.11 (s, 1H), 6.31 (s, 1H), 5.44 (s, 1H), 4.18 (t, J = 6.6 Hz, 2H), 4.08 (s, 2H), 3.88 (s, 3H), 1.71–1.61 (m, 2H), 1.46–1.33 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 166.0, 139.3, 136.3, 134.3, 133.5, 127.5, 65.4, 37.7, 30.6, 27.0, 19.3, 13.8; HRMS (ESI) calcd for $C_{12}H_{18}N_3O_4$ $[M + H]^+$ 268.1292, found 268.1291.

(E)-N,N-Diethyl-3-(1-methyl-4-nitro-1H-pyrazol-5-yl)acrylamide (2e). The GC analysis of the reaction mixture showed the formation of the corresponding (E)-olefination and dialkenylation products (area percentage: >50:1). Purification by flash column chromatography (hexanes/EtOAc = 1:2) provided alkenylated pyrazole 2e as a yellow oil (84 mg, 67% yield). IR (film) 2977, 2934, 1658, 1618, 1362, 1217 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 8.16 (s, 1H), 7.61 (d, J = 15.6 Hz, 1H), 7.54 (d, J = 15.6 Hz, 1H), 3.99 (s, 3H), 3.58–3.43 (m, 4H), 1.31–1.18 (m, 6H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 164.3, 137.4, 136.3, 129.8, 123.6, 42.7, 41.6, 38.9, 15.3, 13.2; HRMS (ESI) calcd for $C_{11}H_{17}N_4O_3$ $[M + H]^+$ 253.1295, found 253.1298.

(E)-1-Methyl-4-nitro-5-styryl-1H-pyrazole (2f). Purification by flash column chromatography (hexanes/EtOAc = 7:1) provided alkenylated pyrazole 2f as a yellow solid (72 mg, 63% yield). Mp 91–93 °C; IR (film) 3060, 1731, 1694, 1681, 1579, 1446 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 8.14 (s, 1H), 7.62–7.56 (m, 2H), 7.48–7.37 (m, 4H), 7.21 (d, J = 16.9 Hz, 1H), 4.05 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 139.7, 138.5, 136.3, 135.2, 132.7, 129.8, 129.0, 127.3, 112.8, 39.4; HRMS (ESI) calcd for $C_{12}H_{12}N_3O_2$ $[M + H]^+$ 230.0924, found 230.0925.

(E)-1-Methyl-5-(4-methylstyryl)-4-nitro-1H-pyrazole (2g). The GC analysis of the reaction mixture showed the formation of the corresponding (E)-olefination and dialkenylation products (area percentage: >50:1). Purification by flash column chromatography (hexanes/EtOAc = 9:2) provided alkenylated pyrazole 2g as a yellow solid (65 mg, 53% yield). Mp 80–81 °C; IR (film) 3585, 3116, 3026, 2922, 1608, 1573, 1225 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 8.13 (s, 1H), 7.48 (d, J = 8.1 Hz, 2H), 7.35 (d, J = 16.9 Hz, 1H), 7.26–7.22 (m, 2H), 7.18 (d, J = 16.9 Hz, 1H), 4.03 (s, 3H), 2.40 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 140.2, 139.7, 138.8, 136.4, 132.6, 132.5, 129.8, 127.3, 111.8, 39.5, 21.5; HRMS (ESI) calcd for $C_{13}H_{14}N_3O_2$ $[M + H]^+$ 244.1081, found 244.1080.

(E)-5-(4-Chlorostyryl)-1-methyl-4-nitro-1H-pyrazole (2h). Purification by flash column chromatography (hexanes/EtOAc = 9:2) provided alkenylated pyrazole 2h as a yellow solid (70 mg, 53% yield). Mp 113–115 °C; IR (film) 3130, 3026, 2925, 1643, 1451, 1319 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 8.14 (s, 1H), 7.52 (d, J = 8.5 Hz, 2H), 7.43–7.32 (m, 3H), 7.17 (d, J = 16.8 Hz, 1H), 4.04 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 138.3, 138.2, 136.4, 135.6, 133.8, 132.8, 129.2, 128.5, 113.4, 39.5; HRMS (ESI) calcd for $C_{12}H_{11}ClN_3O_2$ $[M + H]^+$ 264.0534, found 264.0535.

(E)-1-(2-(1-Methyl-4-nitro-1H-pyrazol-5-yl)vinyl)pyrrolidin-2-one (2i). Purification by flash column chromatography (hexanes/EtOAc = 1:3) provided alkenylated pyrazole 2i as a yellow solid (51 mg, 43% yield). Mp 128–130 °C; IR (film) 3114, 2926, 1716, 1637, 1533, 1490 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 8.07 (s, 1H), 7.69 (d, J = 15.3 Hz, 1H), 6.29 (d, J = 15.3 Hz, 1H), 3.97 (s, 3H), 3.75 (t, J = 7.2 Hz,

2H), 2.60 (t, J = 8.2 Hz, 2H), 2.25 (p, J = 7.7 Hz, 2H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 174.2, 138.1, 136.3, 132.1, 95.9, 44.9, 39.6, 31.1, 17.5; HRMS (ESI) calcd for $C_{10}H_{13}N_4O_3$ $[M + H]^+$ 237.0982, found 237.0986.

(E)-5-(3,3-Dimethylbut-1-en-1-yl)-1-methyl-4-nitro-1H-pyrazole (2j). Purification by flash column chromatography (hexanes/EtOAc = 5:1) provided alkenylated pyrazole 2j as a light yellow solid (9 mg, 9% yield). Mp 56–57 °C; IR (film) 2962, 2906, 2869, 1653, 1472, 1365, 1207 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 8.07 (s, 1H), 6.57 (d, J = 16.8 Hz, 1H), 6.33 (d, J = 16.8 Hz, 1H), 3.90 (s, 3H), 1.19 (s, 9H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 154.2, 139.4, 136.2, 132.4, 110.8, 38.9, 34.7, 29.0; HRMS (ESI) calcd for $C_{10}H_{16}N_3O_2$ $[M + H]^+$ 210.1237, found 210.1229.

4-Nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (5a).^{5c} To a stirred solution of 4-nitro-1H-pyrazole (1.00 g, 8.84 mmol) in THF (10.0 mL) at 0 °C was added sodium hydride 60% in oil (456 mg, 11.4 mmol). After stirring for 30 min at 0 °C, 2-(chloromethoxy)ethyltrimethylsilane (1.70 mL, 9.60 mmol) was added. Stirring was continued for 12 h at 25 °C, and the reaction mixture was treated with water (15 mL) and EtOAc (20 mL) and transferred to a 125 mL separatory funnel. The organic layer was collected, and the aqueous layer was extracted with EtOAc (25 mL \times 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by flash column chromatography (hexanes/EtOAc = 9:1) to provide pyrazole 5a as a white solid (1.40 g, 65% yield). 1H NMR (300 MHz, $CDCl_3$) δ 8.31 (s, 1H), 8.10 (s, 1H), 5.45 (s, 2H), 3.62 (t, J = 8.3 Hz, 2H), 0.94 (t, J = 8.3, 2H), 0.01 (s, 9H).

(E)-N,N-Diethyl-3-(4-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)acrylamide (5b). Purification by flash column chromatography (hexanes/EtOAc = 5:2) provided alkenylated pyrazole 5b as a yellow oil (136 mg, 74% yield). IR (film) 2955, 1659, 1622, 1541, 1504, 1463 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 8.16 (s, 1H), 7.94 (d, J = 15.8 Hz, 1H), 7.50 (d, J = 15.8 Hz, 1H), 5.50 (s, 2H), 3.71 (t, J = 8.5 Hz, 2H), 3.57–3.38 (m, 4H), 1.31–1.17 (m, 6H), 0.93 (t, J = 8.5 Hz, 2H), 0.00 (s, 9H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 164.0, 138.0, 136.5, 134.0, 130.2, 124.7, 79.9, 67.6, 42.5, 41.3, 17.9, 15.1, 13.0, –1.5; HRMS (ESI) calcd for $C_{16}H_{29}N_4O_4Si$ $[M + H]^+$ 369.1953, found 369.1968.

Ethyl 1-Methyl-1H-pyrazole-4-carboxylate (6a).²⁵ Similar to the synthesis of 1a, 6a was prepared from a reaction of ethyl 1H-pyrazole-4-carboxylate (1.00 g, 7.14 mmol), K_2CO_3 (1.08 g, 7.85 mmol), iodomethane (0.67 mL, 10.7 mmol), and acetonitrile (10.0 mL). Purification by flash column chromatography (hexanes/EtOAc = 3:1) provided pyrazole 6a as a colorless oil (677 mg, 62% yield). 1H NMR (300 MHz, $CDCl_3$) δ 7.89 (s, 1H), 7.86 (s, 1H), 4.28 (q, J = 7.1 Hz, 2H), 3.92 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H).

(E)-Ethyl 5-(3-Butoxy-3-oxoprop-1-en-1-yl)-1-methyl-1H-pyrazole-4-carboxylate (6b). Purification by flash column chromatography (hexanes/EtOAc = 6:1) provided alkenylated pyrazole 6b as a brown oil (72 mg, 51% yield). IR (film) 2961, 2874, 1645, 1533, 1467, 1375 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 7.97–7.81 (m, 2H), 6.85 (d, J = 16.4 Hz, 1H), 4.01 (q, J = 7.1 Hz, 2H), 4.23 (t, J = 6.7 Hz, 2H), 4.30 (s, 3H), 1.74–1.65 (m, 2H), 1.50–1.34 (m, 5H), 0.96 (t, J = 7.3 Hz, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 166.4, 162.9, 141.6, 139.3, 129.0, 125.6, 114.3, 64.9, 60.5, 38.8, 30.7, 19.2, 14.3, 13.7; HRMS (ESI) calcd for $C_{14}H_{21}N_2O_4$ $[M + H]^+$ 281.1496, found 281.1503.

1-(1-Methyl-1H-pyrazol-4-yl)ethanone (7a).²⁶ To a stirred solution of 1H-pyrazole (2.00 g, 24.3 mmol) at 25 °C were added acetic anhydride (4.00 mL, 42.5 mmol) and conc. H_2SO_4 (0.020 mL). After heating at 160 °C for 20 h, the reaction mixture was neutralized by 20% aqueous NaOH, treated by water (15 mL) and EtOAc (20 mL) and transferred to a 125 mL separatory funnel. The organic layer was collected, and the aqueous layer was extracted with EtOAc (25 mL \times 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by flash column chromatography (hexanes/EtOAc = 2:1) to provide pyrazole 7a as a white solid (1.47 g, 49% yield). 1H NMR (300 MHz, $CDCl_3$) δ 7.86 (s, 1H), 7.84 (s, 1H), 3.91 (s, 3H), 2.40 (s, 3H).

(*E*)-3-(4-Acetyl-1-methyl-1*H*-pyrazol-5-yl)-*N,N*-diethylacrylamide (**7b**). Purification by flash column chromatography (EtOAc only) provided alkenylated pyrazole **7b** as a brown solid (54 mg, 43% yield). Mp 91–93 °C; IR (film) 3102, 2983, 2937, 1651, 1400, 1313, 1222 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.17 (d, *J* = 15.2 Hz, 1H), 7.93 (s, 1H), 7.60 (d, *J* = 15.2 Hz, 1H), 3.99 (s, 3H), 3.60–3.47 (m, 4H), 2.52 (s, 3H), 1.31 (t, *J* = 7.1 Hz, 3H), 1.20 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 192.6, 165.3, 142.4, 139.9, 127.1, 125.1, 121.4, 42.5, 41.2, 38.0, 29.1, 15.0, 13.1; HRMS (ESI) calcd for C₁₃H₂₀N₃O₂ [M + H]⁺ 250.1550, found 250.1550.

(*E*)-Butyl 3-(4-Acetyl-1-methyl-1*H*-pyrazol-5-yl)acrylate (**7c**). Purification by flash column chromatography (hexanes/EtOAc = 3:1) provided alkenylated pyrazole **7c** as a brown oil (61 mg, 49% yield). IR (film) 2960, 2874, 1716, 1670, 1643, 1400, 1222 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.98–7.79 (m, 2H), 6.91 (d, *J* = 16.4 Hz, 1H), 4.23 (t, *J* = 6.7 Hz, 2H), 4.00 (s, 3H), 2.49 (s, 3H), 1.74–1.65 (m, 2H), 1.50–1.37 (m, 2H), 0.96 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 192.7, 166.4, 141.5, 138.7, 129.3, 126.1, 122.4, 65.0, 38.8, 30.7, 28.9, 19.2, 13.8; HRMS (ESI) calcd for C₁₃H₁₉N₂O₃ [M + H]⁺ 251.1390, found 251.1393.

1-Butyl-4-chloro-1*H*-pyrazole (**8a**). To a stirred solution of 4-chloro-1*H*-pyrazole (1.00 g, 9.75 mmol) in DMF (10.0 mL) at 25 °C were added K₂CO₃ (1.62 g, 11.7 mmol) and 1-bromobutane (1.26 mL, 11.7 mmol). After stirring for 18 h at 25 °C, the reaction mixture was treated with water (15 mL) and EtOAc (20 mL) and transferred to a 125 mL separatory funnel. The organic layer was collected, and the aqueous layer was extracted with EtOAc (25 mL × 2). The organic layers were combined, washed with brine (20 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by flash column chromatography (hexanes/EtOAc = 7:1) to provide pyrazole **8a** as a colorless oil (745 mg, 48% yield). IR (film) 3118, 2961, 2934, 2874, 1450, 1434, 1385 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.40 (s, 1H), 7.35 (s, 1H), 4.06 (t, *J* = 7.1 Hz, 2H), 1.81 (pentet, *J* = 7.4 Hz, 2H), 1.31 (sextet, *J* = 7.4 Hz, 2H), 0.93 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 137.4, 127.0, 109.5, 52.7, 32.3, 19.8, 13.6; HRMS (ESI) calcd for C₇H₁₂ClN₂ [M + H]⁺ 159.0684, found 159.0687.

(*E*)-3-(1-Butyl-4-chloro-1*H*-pyrazol-5-yl)-*N,N*-diethylacrylamide (**8b**). The reaction was conducted for 3 h. Purification by flash column chromatography (hexanes/EtOAc = 2:1) provided alkenylated pyrazole **8b** as a yellow oil (95 mg, 67% yield). IR (film) 3104, 2963, 2874, 1651, 1249, 1219 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.57 (d, *J* = 15.5 Hz, 1H), 7.45 (s, 1H), 7.34 (d, *J* = 15.4 Hz, 1H), 4.20 (t, *J* = 7.3 Hz, 2H), 3.55–3.42 (m, 4H), 1.78 (pentet, *J* = 7.4 Hz, 2H), 1.39–1.24 (m, 5H), 1.20 (t, *J* = 7.1 Hz, 3H), 0.92 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 165.0, 137.6, 133.3, 125.6, 121.4, 109.7, 50.6, 42.5, 41.3, 32.5, 19.7, 15.0, 13.6, 13.2; HRMS (ESI) calcd for C₁₄H₂₃ClN₃O [M + H]⁺ 284.1524, found 284.1523.

4-Chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-pyrazole (**9a**).^{6a} Similar to the synthesis of **5a**, **9a** was prepared from a reaction of 4-chloro-1*H*-pyrazole (3.80 g, 37.1 mmol), sodium hydride 60% in oil (2.20 g, 55.5 mmol), 2-(chloromethoxy)ethyltrimethylsilane (7.20 mL, 40.7 mmol), and THF (18.0 mL). Purification by flash column chromatography (hexanes/EtOAc = 13:1) provided pyrazole **9a** as a colorless oil (8.00 g, 99% yield). ¹H NMR (300 MHz, CDCl₃) δ 7.56 (s, 1H), 7.46 (s, 1H), 5.37 (s, 2H), 3.54 (t, *J* = 8.3 Hz, 2H), 0.90 (t, *J* = 8.3 Hz, 2H), -0.02 (s, 9H).

(*E*)-3-(4-Chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-pyrazol-5-yl)-*N,N*-diethylacrylamide (**9b**). Purification by flash column chromatography (hexanes/EtOAc = 3:1) provided alkenylated pyrazole **9b** as a yellow liquid (114 mg, 64% yield). IR (film) 2954, 1655, 1615, 1483, 1462, 1428 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.67 (d, *J* = 15.7 Hz, 1H), 7.48 (s, 1H), 7.33 (d, *J* = 15.6 Hz, 1H), 5.49 (s, 2H), 3.60–3.42 (m, 6H), 1.26 (t, *J* = 7.1 Hz, 3H), 1.19 (t, *J* = 7.1 Hz, 3H), 0.89 (t, *J* = 8.3 Hz, 2H), -0.03 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 164.9, 138.1, 134.9, 125.3, 122.7, 112.0, 79.3, 66.7, 42.5, 41.3, 17.7, 15.1, 13.2, -1.5; HRMS (ESI) calcd for C₁₆H₂₉ClN₃O₂Si [M + H]⁺ 358.1712, found 358.1714.

4-Chloro-1-methyl-1*H*-pyrazole (**10a**).²⁷ Similar to the synthesis of **1a**, **10a** was prepared from a reaction of 4-chloro-1*H*-pyrazole (500

mg, 4.88 mmol), K₂CO₃ (1.01 g, 7.32 mmol), iodomethane (0.304 mL, 4.88 mmol), and DMF (8.00 mL). Purification by flash column chromatography (hexanes/EtOAc = 3:1) provided pyrazole **10a** as a colorless oil (392 mg, 69% yield). ¹H NMR (300 MHz, CDCl₃) δ 7.40 (s, 1H), 7.34 (s, 1H), 3.86 (s, 3H).

(*E*)-3-(4-Chloro-1-methyl-1*H*-pyrazol-5-yl)-*N,N*-diethylacrylamide (**10b**). Purification by flash column chromatography (hexanes/EtOAc = 2:3) provided alkenylated pyrazole **10b** as a yellow solid (66 mg, 55% yield). Mp 101–103 °C; IR (film) 2976, 2935, 1609, 1382, 1328, 1217 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.57 (d, *J* = 15.9 Hz, 1H), 7.44 (s, 1H), 7.33 (d, *J* = 15.5 Hz, 1H), 3.93 (s, 3H), 3.55–3.43 (m, 4H), 1.28 (t, *J* = 7.1 Hz, 3H), 1.20 (t, *J* = 6.9 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 164.9, 137.5, 134.0, 125.5, 121.5, 110.1, 42.5, 41.3, 38.0, 15.0, 13.2; HRMS (ESI) calcd for C₁₁H₁₇ClN₃O [M + H]⁺ 242.1055, found 242.1052.

4-Bromo-1-butyl-1*H*-pyrazole (**11a**). To a stirred solution of 4-bromo-1*H*-pyrazole (3.00 g, 20.0 mmol) in DMF (18.0 mL) at 25 °C were added K₂CO₃ (6.90 g, 50.0 mmol) and 1-iodobutane (3.40 mL, 30.0 mmol). After stirring for 13 h at 25 °C, the reaction mixture was treated with water (20 mL) and EtOAc (20 mL) and transferred to a 125 mL separatory funnel. The organic layer was collected, and the aqueous layer was extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by flash column chromatography (hexanes/EtOAc = 7:1) to provide pyrazole **11a** as a colorless oil (3.90 g, 96% yield). IR (film) 3118, 2960, 2934, 2873, 1433, 1380 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.44 (s, 1H), 7.39 (s, 1H), 4.09 (t, *J* = 7.1 Hz, 2H), 1.82 (pentet, *J* = 7.4 Hz, 2H), 1.31 (sextet, *J* = 7.4 Hz, 2H), 0.93 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 138.9, 128.7, 92.1, 52.1, 31.9, 19.3, 13.2; HRMS (ESI) calcd for C₇H₁₂BrN₂ [M + H]⁺ 203.0178, found 203.0167.

(*E*)-3-(4-Bromo-1-butyl-1*H*-pyrazol-5-yl)-*N,N*-diethylacrylamide (**11b**). The reaction was conducted for 1 h. Purification by flash column chromatography (hexanes/EtOAc = 5:2) provided alkenylated pyrazole **11b** as a yellow liquid (94 mg, 57% yield). IR (film) 2963, 2933, 2873, 1653, 1611, 1483, 1461 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.56 (d, *J* = 15.4 Hz, 1H), 7.49 (s, 1H), 7.42 (d, *J* = 15.5 Hz, 1H), 4.21 (t, *J* = 7.3 Hz, 2H), 3.57–3.41 (m, 4H), 1.79 (pentet, *J* = 7.5 Hz, 2H), 1.39–1.24 (m, 5H), 1.20 (t, *J* = 7.1 Hz, 3H), 0.92 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 164.8, 139.8, 134.4, 125.8, 121.7, 93.8, 50.5, 42.4, 41.3, 32.4, 19.7, 15.0, 13.5, 13.1; HRMS (ESI) calcd for C₁₄H₂₃BrN₃O [M + H]⁺ 328.1019, found 328.1015.

4-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-pyrazole (**12a**).^{4a} Similar to the synthesis of **5a**, **12a** was prepared from a reaction of 4-bromo-1*H*-pyrazole (1.00 g, 6.80 mmol), sodium hydride 60% in oil (408 mg, 10.2 mmol), 2-(chloromethoxy)ethyltrimethylsilane (1.26 mL, 7.14 mmol), and THF (10.0 mL). Purification by flash column chromatography (hexanes/EtOAc = 20:1) provided pyrazole **12a** as a colorless oil (1.50 g, 80% yield). ¹H NMR (300 MHz, CDCl₃) δ 7.59 (s, 1H), 7.50 (s, 1H), 5.39 (s, 2H), 3.54 (t, *J* = 8.3 Hz, 2H), 0.90 (t, *J* = 8.3 Hz, 2H), -0.02 (s, 9H).

(*E*)-3-(4-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-pyrazol-5-yl)-*N,N*-diethylacrylamide (**12b**). Purification by flash column chromatography (hexanes/EtOAc = 3:1) provided alkenylated pyrazole **12b** as a yellow oil (82 mg, 41% yield). IR (film) 2954, 2932, 1656, 1615, 1482, 1460 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.64 (d, *J* = 15.6 Hz, 1H), 7.49 (s, 1H), 7.37 (d, *J* = 15.6 Hz, 1H), 5.49 (s, 2H), 3.59–3.40 (m, 6H), 1.25 (t, *J* = 7.0 Hz, 3H), 1.17 (t, *J* = 7.1 Hz, 3H), 0.88 (t, *J* = 8.3 Hz, 2H), -0.05 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 165.0, 140.4, 136.5, 125.9, 123.3, 96.8, 79.4, 66.8, 42.6, 41.4, 17.8, 15.2, 13.3, -1.4; HRMS (ESI) calcd for C₁₆H₂₉BrN₃O₂Si [M + H]⁺ 402.1207, found 402.1202.

4-Methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-pyrazole (**13a**).²⁸ Similar to the synthesis of **5a**, **13a** was prepared from a reaction of 4-methyl-1*H*-pyrazole (500 mg, 6.09 mmol), sodium hydride 60% in oil (400 mg, 10.0 mmol), 2-(chloromethoxy)ethyltrimethylsilane (1.27 mL, 7.20 mmol), and THF (10.0 mL). Purification by flash column chromatography (hexanes/EtOAc = 12:1) provided pyrazole **13a** as a colorless oil (1.04 g, 80% yield). ¹H

NMR (300 MHz, CDCl₃) δ 7.35 (s, 1H), 7.33 (s, 1H), 5.36 (s, 2H), 3.53 (t, J = 8.3 Hz, 2H), 2.09 (s, 3H), 0.90 (t, J = 8.3 Hz, 2H), -0.03 (s, 3H).

(*E*)-*N,N*-Diethyl-3-(4-methyl-1-((2-trimethylsilyl)ethoxy)methyl)-1*H*-pyrazol-5-yl)acrylamide (**13b**). Purification by flash column chromatography (hexanes/EtOAc = 2:1) provided alkenylated pyrazole **13b** as a yellow oil (117 mg, 69% yield). IR (film) 2954, 1653, 1612, 1484, 1459, 1427 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J = 15.7 Hz, 1H), 7.34 (s, 1H), 6.93 (d, J = 15.6 Hz, 1H), 5.48 (s, 2H), 3.59 (t, J = 8.3 Hz, 2H), 3.55–3.41 (m, 4H), 2.18 (s, 3H), 1.28–1.16 (m, 6H), 0.89 (t, J = 8.3 Hz, 2H), -0.04 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 165.4, 140.0, 136.2, 127.5, 120.8, 118.9, 78.7, 66.2, 42.4, 41.2, 17.8, 15.1, 13.2, 10.0, -1.5; HRMS (ESI) calcd for C₁₇H₃₂N₃O₂Si [M + H]⁺ 338.2258, found 338.2255.

1-Butyl-4-phenyl-1*H*-pyrazole (**14a**). To an 8 mL glass vial equipped with a magnetic bar were sequentially added Cs₂CO₃ (320 mg, 0.98 mmol), *N*-butyl-4-bromopyrazole **11a** (100 mg, 0.49 mmol), 1,4-dioxane (1.0 mL, 0.50 M), phenylboronic acid (66 mg, 0.54 mmol), Pd(OAc)₂ (5.5 mg, 0.0245 mmol), and PCy₃HBF₄ (18 mg, 0.049 mmol). The reaction mixture was purged with nitrogen through a Teflon-lined cap. Then the cap was replaced with a new Teflon-lined solid cap. After moving the reaction vial to a preheated reaction block, the reaction mixture was stirred at 100 °C. After 12 h, the reaction mixture was cooled to 25 °C and concentrated. The residue was purified by flash column chromatography (hexanes/EtOAc = 10:1) to provide pyrazole **14a** as a colorless oil (183 mg, 91% yield). IR (film) 3035, 2959, 2933, 2873, 1608, 1565, 1460 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.78 (s, 1H), 7.63 (s, 1H), 7.48 (d, J = 7.6 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.22 (t, J = 7.2 Hz, 1H), 4.15 (t, J = 7.1 Hz, 2H), 1.89 (pentet, J = 7.3 Hz, 2H), 1.36 (sextet, J = 7.5 Hz, 2H), 0.96 (t, J = 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 136.5, 132.7, 128.9, 126.3, 125.9, 125.5, 122.7, 52.2, 32.5, 19.9, 13.7; HRMS (ESI) calcd for C₁₃H₁₇N₂ [M + H]⁺ 201.1386, found 201.1376.

(*E*)-3-(1-Butyl-4-phenyl-1*H*-pyrazol-5-yl)-*N,N*-diethylacrylamide (**14b**). Purification by flash column chromatography (hexanes/EtOAc = 3:2) provided alkenylated pyrazole **14b** as a yellow oil (86 mg, 53% yield). IR (film) 2962, 2932, 2873, 1651, 1609, 1486, 1462 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.63 (d, J = 15.4 Hz, 1H), 7.48 (s, 1H), 7.43–7.34 (m, 4H), 7.33–7.28 (m, 1H), 6.48 (d, J = 15.5 Hz, 1H), 4.25 (t, J = 7.3 Hz, 2H), 3.39 (q, J = 7.1 Hz, 2H), 3.01 (q, J = 7.0 Hz, 2H), 1.86, (pentet, J = 7.5 Hz, 2H), 1.39 (sextet, J = 7.5 Hz, 2H), 1.12 (t, J = 7.1 Hz, 3H), 0.96 (t, J = 7.3 Hz, 3H), 0.88 (t, J = 7.1 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 165.1, 138.7, 134.4, 133.8, 129.2, 128.8, 127.4, 127.2, 122.9, 121.2, 50.0, 42.1, 41.2, 32.8, 20.0, 14.9, 13.8, 13.2; HRMS (ESI) calcd for C₂₀H₂₈N₃O [M + H]⁺ 326.2227, found 326.2221.

2-Methyl-2*H*-indazole (**15a**).²⁹ To a stirred solution of 1*H*-indazole (1.00 g, 8.47 mmol) in acetone (10.0 mL) at 0 °C was added potassium hydroxide (1.41 g, 25.2 mmol). After stirring for 1 h at 0 °C, iodomethane (0.98 mL, 15.7 mmol) was added to the flask, and the mixture was stirred for 15 h at 25 °C. The potassium hydroxide was removed by filtration and the filtrate was concentrated, and the residue was purified by flash column chromatography (hexanes/EtOAc = 1:1) provided indazole **15a** as a brown oil (421 mg, 38% yield) and indazole **16a** as a yellow solid (619 mg, 55% yield). ¹H NMR (300 MHz, CDCl₃) δ 7.90 (s, 1H), 7.73–7.60 (m, 2H), 7.36–7.26 (m, 1H), 7.14–7.04 (m, 1H), 4.23 (s, 3H).

1-Methyl-1*H*-indazole (**16a**).²⁹ ¹H NMR (300 MHz, CDCl₃) δ 8.00 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.41 (d, J = 3.7 Hz, 2H), 7.22–7.09 (m, 1H), 4.10 (s, 3H).

(*E*)-*N,N*-Diethyl-3-(2-methyl-2*H*-indazol-3-yl)acrylamide (**15b**). Purification by flash column chromatography (hexanes/EtOAc = 1:3) provided alkenylated indazole **15b** as an orange oil (83 mg, 64% yield). IR (film) 2975, 2933, 1642, 1594, 1487, 1447 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.94 (d, J = 15.3 Hz, 1H), 7.74 (t, J = 9.7 Hz, 2H), 7.32 (t, J = 7.6 Hz, 1H), 7.19 (t, J = 7.5 Hz, 1H), 7.06 (d, J = 15.3 Hz, 1H), 4.24 (s, 3H), 3.60–3.43 (m, 4H), 1.31 (t, J = 7.0 Hz, 3H), 1.20 (t, J = 7.0 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 165.1, 147.9, 131.1, 127.6, 126.1, 123.4, 120.7, 119.7, 118.6, 118.1, 42.4, 41.3, 38.5,

15.1, 13.2; HRMS (ESI) calcd for C₁₅H₂₀N₃O [M + H]⁺ 258.1601, found 258.1603.

(*E*)-Butyl 3-(2-Methyl-2*H*-indazol-3-yl)acrylate (**15c**).⁹ Purification by flash column chromatography (hexanes/EtOAc = 4:1) provided alkenylated indazole **15c** (93 mg, 72% yield). ¹H NMR (300 MHz, CDCl₃) δ 7.93 (d, J = 15.9 Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.6, 1H), 7.40–7.32 (m, 1H), 7.28–7.22 (m, 2H), 6.67 (d, J = 15.9 Hz, 1H), 4.35–4.19 (m, 5H), 1.78–1.67 (m, 2H), 1.54–1.40 (m, 2H), 0.99 (t, J = 7.3 Hz, 3H).

(*E*)-*N,N*-Diethyl-3-(1-methyl-1*H*-indazol-3-yl)acrylamide (**16b**). Purification by flash column chromatography (hexanes/EtOAc = 5:1) provided alkenylated indazole **16b** as a yellow oil (54 mg, 42% yield). Mp 103–105 °C; IR (film) 2974, 2932, 1650, 1602, 1490, 1449 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.03 (d, J = 15.4 Hz, 1H), 7.90 (d, J = 8.1 Hz, 1H), 7.57–7.41 (m, 2H), 7.35–7.14 (m, 2H), 4.13 (s, 3H), 3.65–3.49 (m, 4H), 1.32 (t, J = 6.8 Hz, 3H), 1.23 (t, J = 6.8 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 165.8, 141.1, 140.3, 132.4, 126.6, 123.0, 121.6, 120.3, 118.2, 109.4, 42.4, 41.1, 35.8, 15.2, 13.3; HRMS (ESI) calcd for C₁₅H₂₀N₃O [M + H]⁺ 258.1601, found 258.1603.

(*E*)-4-Nitro-1-(4-phenylbut-3-en-1-yl)-1*H*-pyrazole (**17a**). To a stirred solution of 4-nitro-1*H*-pyrazole (1.00 g, 8.84 mmol) in DMF (5.00 mL) at 25 °C were added K₂CO₃ (1.47 g, 10.6 mmol) and 4-bromo-1-butene (1.08 mL, 10.61 mmol). After 14 h, the reaction mixture was treated with water (15 mL) and EtOAc (20 mL). After shaking in a 125 mL separatory funnel, the separated aqueous phase was extracted with EtOAc (20 mL \times 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by flash column chromatography (hexane/EtOAc = 4:1) to provide 1-(but-3-en-1-yl)-4-nitro-1*H*-pyrazole as a white solid (1.47 mg, 99% yield). ¹H NMR (300 MHz, CDCl₃) δ 8.10 (s, 1H), 8.08 (s, 1H), 5.85–5.62 (m, 1H), 5.19–4.98 (m, 2H), 4.22 (t, J = 6.9 Hz, 2H), 2.65 (q, J = 6.9 Hz, 2H). Following a reported procedure, the Heck reaction was carried out.³⁰ To an 8 mL glass vial equipped with a magnetic bar were sequentially added 1-(but-3-en-1-yl)-4-nitro-1*H*-pyrazole (167 mg, 1.0 mmol), *N,N*-diisopropylethylamine (281 μ L, 2.0 mmol), acetonitrile (2.00 mL, 0.50 M), bromobenzene (105 μ L, 1.0 mmol), Pd(OAc)₂ (11.2 mg, 0.050 mmol), and P(*o*-tolyl)₃ (45.6 mg, 0.15 mmol). The reaction mixture was purged with nitrogen through a Teflon-lined cap followed by replacement with a new Teflon-lined solid cap. After the reaction vial was moved to a preheated reaction block, the reaction mixture was stirred at 90 °C. After 6 h, the reaction mixture was cooled to 25 °C and concentrated. The residue was purified by flash column chromatography (hexanes/EtOAc = 11:2) to provide pyrazole **17a** as a yellow solid (143 mg, 59% yield). Mp 123–124 °C; IR (film) 3131, 3027, 1530, 1509, 1408, 1301 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 8.10 (s, 1H), 7.39–7.14 (m, 5H), 6.43 (d, J = 15.8 Hz, 1H), 6.18–5.98 (m, 1H), 4.28 (t, J = 6.9 Hz, 2H), 2.82 (q, J = 6.9 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 136.6, 135.9, 135.6, 133.8, 128.7, 128.6, 127.8, 126.2, 124.1, 53.2, 33.3; HRMS (EI) calcd for C₁₃H₁₃N₃O₂ [M]⁺ 243.1008, found 243.1010.

(*E*)-4-Benzylidene-3-nitro-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazole (**17b**). For the intramolecular alkenylation reaction, **17a** (73 mg, 0.30 mmol), 1,4-dioxane (3.0 mL, 0.10 M), Cu(OAc)₂·H₂O (120 mg, 0.60 mmol), pyridine (4.8 μ L, 0.060 mmol), and Pd(OAc)₂ (6.7 mg, 0.030 mmol) were used. Purification by flash column chromatography (hexanes/EtOAc = 3:1) provided alkenylated pyrazole **17b** as a yellow solid (34 mg, 47% yield). Mp 144–146 °C. IR (film) 2924, 1539, 1495, 1427, 1388, 1304 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.16 (s, 2H), 7.58–7.30 (m, 5H), 4.39 (t, J = 6.7 Hz, 2H), 3.69–3.55 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 136.0, 131.8, 129.5, 128.9, 128.7, 125.7, 48.3, 32.4, 29.8; HRMS (ESI) calcd for C₁₃H₁₂N₃O₂ [M + H]⁺ 242.0924, found 242.0928.

(*E*)-Ethyl 4-(4-(4-Nitro-1*H*-pyrazol-1-yl)but-1-en-1-yl)benzoate (**18a**). To an 8 mL glass vial equipped with a magnetic bar were sequentially added 1-(but-3-en-1-yl)-4-nitro-1*H*-pyrazole, the intermediate in the preparation of **17a** (134 mg, 0.80 mmol), *N,N*-diisopropylethylamine (279 μ L, 1.6 mmol), acetonitrile (1.60 mL, 0.50 M), ethyl-4-bromobenzoate (131 μ L, 0.80 mmol), Pd(OAc)₂ (18.0 mg, 0.080 mmol), and P(*o*-tolyl)₃ (73.0 mg, 0.24 mmol). The reaction

mixture was purged with nitrogen through a Teflon-lined cap followed by replacement with a new Teflon-lined solid cap. After the reaction vial was moved to a preheated reaction block, the reaction mixture was stirred at 90 °C. After 6 h, the reaction mixture was cooled to 25 °C and concentrated. The residue was purified by flash column chromatography (hexanes/EtOAc = 5:2) to provide pyrazole **18a** as a white solid (152 mg, 60% yield). Mp 99–100 °C; IR (film) 3130, 2982, 1711, 1607, 1531, 1510, 1408, 1302 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 8.10 (s, 1H), 7.98 (d, *J* = 8.3 Hz, 2H), 7.35 (d, *J* = 8.3 Hz, 2H), 6.46 (d, *J* = 15.5 Hz, 1H), 6.29–6.13 (m, 1H), 4.45–4.25 (m, 4H), 2.85 (q, *J* = 7.2 Hz, 2H), 1.39 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 166.3, 140.9, 135.9, 135.6, 132.9, 129.9, 129.5, 128.6, 126.9, 126.0, 61.0, 52.9, 33.4, 14.4; HRMS (ESI) calcd for C₁₆H₁₈N₃O₄ [M + H]⁺ 316.1292, found 316.1299.

(*E*)-Ethyl 4-((3-Nitro-5,6-dihydro-4H-pyrrolo[1,2-*b*]pyrazol-4-ylidene)methyl)benzoate (**18b**). For the intramolecular alkenylation reaction, **18a** (79 mg, 0.25 mmol), 1,4-dioxane (2.5 mL, 0.10 M), Cu(OAc)₂·H₂O (100 mg, 0.50 mmol), pyridine (4.0 μL, 0.050 mmol), and Pd(OAc)₂ (5.6 mg, 0.025 mmol) were used. Purification by flash column chromatography (hexanes/EtOAc = 9:4) provided alkenylated pyrazole **18b** as a yellow solid (44 mg, 56% yield). Mp 161–163 °C. IR (film) 3101, 2979, 1715, 1605, 1538, 1411, 1387 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.20 (s, 2H), 8.10 (d, *J* = 7.4 Hz, 2H), 7.54 (d, *J* = 7.8 Hz, 2H), 4.48–4.35 (m, 4H), 3.66 (t, *J* = 5.1 Hz, 2H), 1.42 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 166.1, 146.2, 143.4, 142.0, 140.2, 130.4, 130.1, 130.0, 129.2, 127.8, 61.3, 48.3, 32.5, 14.4; HRMS (ESI) calcd for C₁₆H₁₅N₃O₄Na [M + Na]⁺ 336.0955, found 336.0959.

(*E*)-4-Nitro-1-(5-phenylpent-4-en-1-yl)-1H-pyrazole (**19a**). Following a reported procedure, the Heck reaction was carried out.³⁰ To an 8 mL glass vial equipped with a magnetic stir bar were sequentially added **20a** (181 mg, 1.0 mmol), *N,N*-diisopropylethylamine (0.350 μL, 2.0 mmol), acetonitrile (2.00 mL, 0.50 M), bromobenzene (105 μL, 1.0 mmol), Pd(OAc)₂ (11.2 mg, 0.050 mmol), and P(*o*-tolyl)₃ (45.7 mg, 0.15 mmol). The reaction mixture was purged with argon through a Teflon-lined cap followed by replacement with a new Teflon-lined solid cap. After the reaction vial was moved to a preheated reaction block, the reaction mixture was stirred at 90 °C. After 12 h, the reaction mixture was cooled to 25 °C and concentrated. The residue was purified by recrystallization with EtOAc and hexanes to provide pyrazole **19a** as a white solid (57 mg, 22% yield). Mp 66–67 °C; IR (film) 3131, 3024, 2922, 1529, 1480, 1369 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 8.09 (s, 1H), 7.37–7.27 (m, 4H), 7.24–7.18 (m, 1H), 6.41 (d, *J* = 16.2 Hz, 1H), 6.22–6.06 (m, 1H), 4.20 (t, *J* = 6.7 Hz, 2H), 2.26 (q, *J* = 7.2 Hz, 2H), 2.11 (d, *J* = 7.3 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 137.1, 136.0, 131.8, 128.7, 128.6, 128.0, 127.5, 126.1, 52.8, 29.8, 29.2; HRMS (EI) calcd for C₁₄H₁₅N₃O₂ [M]⁺ 257.1164, found 257.1163.

(*E*)-4-Benzylidene-3-nitro-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridine (**19b**). For the intramolecular alkenylation reaction, **19a** (38 mg, 0.15 mmol), 1,4-dioxane (1.5 mL, 0.10 M), Cu(OAc)₂·H₂O (60 mg, 0.30 mmol), pyridine (2.4 μL, 0.030 mmol), and Pd(OAc)₂ (3.4 mg, 0.015 mmol) were used. Purification by flash column chromatography (hexanes/EtOAc = 7:2) provided alkenylated pyrazole **19b** as a yellow solid (21 mg, 56% yield). Mp 77–78 °C; IR (film) 2929, 1523, 1426, 1343, 1254 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.20 (s, 1H), 8.09 (s, 1H), 7.48–7.28 (m, 5H), 4.29 (t, *J* = 6.2 Hz, 2H), 2.89 (t, *J* = 5.5 Hz, 2H), 2.10 (pentet, *J* = 6.3 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 138.8, 138.2, 136.2, 135.9, 129.5, 128.5, 128.1, 123.4, 49.6, 25.2, 22.7; HRMS (ESI) calcd for C₁₄H₁₄N₃O₂ [M + H]⁺ 256.1081, found 256.1073.

4-Nitro-1-(pent-4-en-1-yl)-1H-pyrazole (**20a**). To a stirred solution of 4-nitro-1H-pyrazole (500 mg, 4.42 mmol) in DMF (3.00 mL) at 25 °C were added K₂CO₃ (732 mg, 5.30 mmol) and 5-bromo-1-pentene (0.630 mL, 5.30 mmol). After 13 h, the reaction mixture was treated with water (15 mL) and EtOAc (20 mL). After shaking in a 125 mL separatory funnel, the separated aqueous phase was extracted with EtOAc (20 mL × 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by flash column

chromatography (hexanes/EtOAc = 6:1) to provide pyrazole **20a** as a yellow oil (757 mg, 94% yield). IR (film) 3133, 3079, 2978, 2940, 2852, 1506, 1407, 1302 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.11 (s, 1H), 8.08 (s, 1H), 5.89–5.63 (m, 1H), 5.16–4.94 (m, 2H), 4.16 (t, *J* = 6.6 Hz, 2H), 2.13–1.96 (m, 4H); ¹³C NMR (75 MHz, CDCl₃) δ 136.4, 135.8, 135.6, 128.5, 116.5, 52.7, 30.3, 28.7; HRMS (ESI) calcd for C₈H₁₂N₃O₂ [M + H]⁺ 182.0924, found 182.0914.

4-Methylene-3-nitro-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridine (**20b**). For the intramolecular alkenylation reaction, **20a** (91 mg, 0.50 mmol), 1,4-dioxane (5.0 mL, 0.10 M), Cu(OAc)₂·H₂O (200 mg, 1.0 mmol), pyridine (8.1 μL, 0.10 mmol), and Pd(OAc)₂ (11 mg, 0.050 mmol) were used. Purification by flash column chromatography (hexanes/EtOAc = 4:1) provided alkenylated pyrazole **20b** as a yellow solid (40 mg, 45% yield). Mp 44–47 °C; IR (film) 3129, 2966, 2855, 1531, 1504, 1417 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.17 (s, 1H), 6.61 (s, 1H), 5.65 (s, 1H), 4.28 (t, *J* = 6.2 Hz, 2H), 2.71–2.54 (m, 2H), 2.21–2.07 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 138.4, 136.7, 130.0, 128.8, 122.1, 49.7, 31.0, 22.7; HRMS (ESI) calcd for C₈H₁₀N₃O₂ [M + H]⁺ 180.0768, found 180.0767.

1-(Hex-5-en-1-yl)-4-nitro-1H-pyrazole (**21a**). Similar to the synthesis of **20a**, **21a** was prepared from a reaction of 4-nitro-1H-pyrazole (599 mg, 5.30 mmol), K₂CO₃ (879 mg, 6.36 mmol), 6-bromo-1-hexene (0.850 mL, 6.36 mmol), and DMF (8.00 mL). Purification by flash column chromatography (hexanes/EtOAc = 5:1) provided pyrazole **21a** as a white solid (1.01 g, 98% yield). Mp 27–29 °C; IR (film) 3134, 3077, 2933, 2860, 1530, 1510 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.12 (s, 1H), 8.07 (s, 1H), 5.85–5.67 (m, 1H), 5.12–4.87 (m, 2H), 4.15 (t, *J* = 7.1 Hz, 2H), 2.16–2.04 (m, 2H), 1.99–1.87 (m, 2H), 1.48–1.35 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 137.6, 135.5, 128.4, 115.2, 53.2, 32.9, 29.0, 25.4; HRMS (ESI) calcd for C₉H₁₄N₃O₂ [M + H]⁺ 196.1081, found 196.1074.

4-Methylene-3-nitro-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*]azepine (**21b**). For the intramolecular alkenylation reaction, **21a** (98 mg, 0.50 mmol), 1,4-dioxane (5.0 mL, 0.10 M), Cu(OAc)₂·H₂O (200 mg, 1.0 mmol), pyridine (8.1 μL, 0.10 mmol), and Pd(OAc)₂ (11 mg, 0.050 mmol) were used. Purification by flash column chromatography (hexanes/EtOAc = 4:1) provided alkenylated pyrazole **21b** as a white solid (56 mg, 58% yield). Mp 58–60 °C; IR (film) 3126, 2937, 2857, 1549, 1504, 1466 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.01 (s, 1H), 5.73 (s, 1H), 5.52 (s, 1H), 4.26 (t, *J* = 4.9 Hz, 2H), 2.47 (t, *J* = 5.6 Hz, 3H), 1.98–1.86 (m, 4H); ¹³C NMR (75 MHz, CDCl₃) δ 142.5, 135.9, 134.2, 124.6, 54.8, 35.4, 30.6, 26.8; HRMS (ESI) calcd for C₉H₁₂N₃O₂ [M + H]⁺ 194.0924, found 194.0925.

Butyl 1-Methyl-1,4-dihydropyrrolo[3,2-*c*]pyrazole-5-carboxylate (**22**). To an 8 mL glass vial equipped with a magnetic bar were sequentially added **2a** (121 mg, 0.48 mmol), PPh₃ (315 mg, 1.20 mmol), and *o*-dichlorobenzene (2.00 mL, 0.24 M). The reaction mixture was stirred at 180 °C. After 24 h, the reaction mixture was cooled to 25 °C. The residue was purified by flash column chromatography (hexanes/EtOAc = 3:1) to provide pyrazole **22** as a brown solid (54 mg, 51% yield). Mp 89–90 °C; IR (film) 3227, 2954, 2869, 1694, 1528, 1455 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.44 (br s, 1H), 7.37 (s, 1H), 6.70 (s, 1H), 4.32 (t, *J* = 6.6 Hz, 2H), 3.96 (s, 3H), 1.74 (pentet, *J* = 7.0 Hz, 2H), 1.47 (sextet, *J* = 7.4 Hz, 2H), 0.98 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 162.4, 138.6, 130.4, 129.5, 119.3, 93.7, 64.9, 37.3, 30.8, 19.3, 13.8; HRMS (ESI) calcd for C₁₁H₁₆N₃O₂ [M + H]⁺ 222.1237, found 222.1231.

1-Methyl-5-phenyl-1,4-dihydropyrrolo[3,2-*c*]pyrazole (**23**). To an 8 mL glass vial equipped with a magnetic bar were sequentially added **2f** (115 mg, 0.50 mmol), PPh₃ (328 mg, 1.25 mmol), and *o*-dichlorobenzene (2.00 mL, 0.25 M). The reaction mixture was stirred at 180 °C. After 36 h, the reaction mixture was cooled to 25 °C. The residue was purified by flash column chromatography (hexanes/EtOAc = 2:3) to provide pyrazole **23** as a brown solid (54 mg, 55% yield). Mp 185–186 °C; IR (film) 3177, 3062, 2931, 2854, 1602, 1503 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.83 (br s, 1H), 7.58–7.56 (m, 2H), 7.42 (t, *J* = 7.7 Hz, 2H), 7.34–7.31 (m, 2H), 6.34 (s, 1H), 3.97 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 141.7, 140.4, 133.2, 129.1, 128.3, 127.7, 124.9, 118.9, 86.7, 37.3; HRMS (ESI) calcd for C₁₂H₁₂N₃ [M + H]⁺ 198.1026, found 198.1026.

(Z)-2-(4,5-Diphenyl-1-((2-(trimethylsilyl)ethoxy)methyl)cyclopenta[c]pyrazol-6(1H)-ylidene)-N,N-diethylacetamide (**24**). To an 8 mL glass vial equipped with a magnetic bar were sequentially added K_2CO_3 (116 mg, 0.84 mmol), **12b** (170 mg, 0.42 mmol), *N,N*-dimethylacetamide (1.0 mL, 0.42 M), 1,2-diphenylacetylene (75 mg, 0.42 mmol), $Pd(OAc)_2$ (4.7 mg, 0.021 mmol), and PCy_3HBF_4 (23 mg, 0.063 mmol). The reaction mixture was purged with nitrogen through a Teflon-lined cap. Then the cap was replaced with a new Teflon-lined solid cap. After moving the reaction vial to a preheated reaction block, the reaction mixture was stirred at 120 °C. After 14 h, the reaction mixture was cooled to 25 °C and concentrated. The residue was purified by flash column chromatography (hexanes/EtOAc = 9:2) to provide pyrazole **24** as a red oil (125 mg, 60% yield). IR (film) 2952, 2895, 1625, 1488, 1458, 1432 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 7.49 (s, 1H), 7.39–7.27 (m, 6H), 7.26–7.19 (m, 4H), 6.38 (s, 1H), 5.64 (s, 2H), 3.54–3.41 (m, 4H), 3.30 (q, $J = 7.1$ Hz, 2H), 1.21 (t, $J = 7.2$ Hz, 3H), 1.11 (t, $J = 7.1$, 3H), 0.84 (t, $J = 8.5$ Hz, 2H), -0.04 (s, 9H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 166.6, 140.5, 135.9, 135.0, 134.7, 134.5, 134.3, 133.9, 131.0, 130.2, 128.6, 128.5, 128.2, 127.9, 127.6, 126.0, 80.4, 66.1, 43.1, 40.0, 17.8, 14.0, 13.1, -1.4 ; HRMS (ESI) calcd for $C_{30}H_{38}N_3O_2Si$ $[M + H]^+$ 500.2728, found 500.2739.

■ ASSOCIATED CONTENT

📄 Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b02398.

1H and ^{13}C spectra for all new compounds (PDF)

Crystallographic data for **17b** (CIF)

Crystallographic data for **19b** (CIF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: jmjoo@pusan.ac.kr.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2014R1A1A1004713). This study was also supported by the Research Fund Program of the Research Institute for Basic Sciences, Pusan National University, Korea, 2015 Project No. RIBS-PNU-2015-103. This research was performed as a cooperation project (SI1512, the Korea Chemical Bank) and supported by the Korea Research Institute of Chemical Technology (KRICT).

■ REFERENCES

- (1) (a) *Metal-Catalyzed Cross-Coupling Reactions and More*; de Meijere, A.; Bräse, S.; Oestreich, M., Eds.; VCH: Weinheim, 2014; Vol. 3. (b) Wencel-Delord, J.; Glorius, F. *Nat. Chem.* **2013**, *5*, 369–375. (c) Chen, D. Y.-K.; Youn, S. W. *Chem.-Eur. J.* **2012**, *18*, 9452–9474.
- (2) Yet, L. Pyrazoles. In *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R., Ramsden, C. A., Scriven, E. F. V., Taylor, R. J. K., Eds.; Elsevier: Oxford, U.K., 2008; Vol. 4, pp 1–141.
- (3) (a) Janin, Y. L. *Chem. Rev.* **2012**, *112*, 3924–3958. (b) Ivachtchenko, A. V.; Kravchenko, D. V.; Zheludeva, V. I.; Pershin, D. G. *J. Heterocyclic Chem.* **2004**, *41*, 931–939.
- (4) (a) Goikhman, R.; Jacques, T. L.; Sames, D. *J. Am. Chem. Soc.* **2009**, *131*, 3042–3048. (b) Choi, Y. L.; Lee, H.; Kim, B. T.; Choi, K.; Heo, J.-N. *Adv. Synth. Catal.* **2010**, *352*, 2041–2049. (c) Santelli, M.; Doucet, H.; Fall, Y. *Synthesis* **2010**, *2010*, 127–135. (d) Beladhria, A.; Beydoun, K.; Ben Ammar, H.; Ben Salem, R.; Doucet, H. *Synthesis*

2011, 2553–2560. (e) Bellina, F.; Lessi, M.; Manzini, C. *Eur. J. Org. Chem.* **2013**, *2013*, 5621–5630.

- (5) Cl: (a) Mateos, C.; Mendiola, J.; Carpintero, M.; Mínguez, J. M. *Org. Lett.* **2010**, *12*, 4924–4927. (b) Yan, T.; Chen, L.; Bruneau, C.; Dixneuf, P. H.; Doucet, H. *J. Org. Chem.* **2012**, *77*, 7659–7664. NO_2 : (c) Hanan, E. J.; van Abbema, A.; Barrett, K.; Blair, W. S.; Blaney, J.; Chang, C.; Eigenbrot, C.; Flynn, S.; Gibbons, P.; Hurley, C. A.; Kenny, J. R.; Kulagowski, J.; Lee, L.; Magnuson, S. R.; Morris, C.; Murray, J.; Pastor, R. M.; Rawson, T.; Siu, M.; Ultsch, M.; Zhou, A.; Sampath, D.; Lyssikatos, J. P. *J. Med. Chem.* **2012**, *55*, 10090–10107. (d) Iaroshenko, V. O.; Gevorgyan, A.; Davydova, O.; Villinger, A.; Langer, P. *J. Org. Chem.* **2014**, *79*, 2906–2915. (e) Jung, H.; Bae, S.; Jang, H.-L.; Joo, J. M. *Bull. Korean Chem. Soc.* **2014**, *35*, 3009–3014. CHO: (f) Smari, I.; Yousef, C.; Yuan, K.; Beladhria, A.; Ammar, H. B.; Hassine, B. B.; Doucet, H. *Eur. J. Org. Chem.* **2014**, *2014*, 1778–1786. CF_3 : (g) Gaulier, S. M.; McKay, R.; Swain, N. A. *Tetrahedron Lett.* **2011**, *52*, 6000–6002. $N-SO_2NMe_2$: (h) Kumpulainen, E. T. T.; Pohjakallio, A. *Adv. Synth. Catal.* **2014**, *356*, 1555–1561. Br: (i) Brahim, M.; Smari, I.; Ben Ammar, H.; Ben Hassine, B.; Soule, J.-F.; Doucet, H. *Org. Chem. Front.* **2015**, *2*, 917–926.

(6) (a) Bae, S.; Jang, H.-L.; Jung, H.; Joo, J. M. *J. Org. Chem.* **2015**, *80*, 690–697. (b) Jang, H.-L.; Kim, H. T.; Cho, E. J.; Joo, J. M. *Asian J. Org. Chem.* **2015**, *4*, 1386–1391.

(7) For reviews of catalytic C–H alkenylation reactions, see: (a) Le Bras, J.; Muzart, J. *Chem. Rev.* **2011**, *111*, 1170–1214. (b) Wu, Y.; Wang, J.; Mao, F.; Kwong, F. Y. *Chem.-Asian J.* **2014**, *9*, 26–47. (c) Satoh, T.; Miura, M. C–H Bond Alkenylation. In *Metal-Catalyzed Cross-Coupling Reactions and More*; de Meijere, A.; Bräse, S.; Oestreich, M., Eds.; VCH: Weinheim, 2014; Vol. 3, pp 1389–1426.

(8) (a) Itahara, T.; Kawasaki, K.; Ousetto, F. *Bull. Chem. Soc. Jpn.* **1984**, *57*, 3488–3493. (b) Chappell, B.; Dedman, N.; Wheeler, S. *Tetrahedron Lett.* **2011**, *52*, 3223–3225. (c) Wang, X.; Fang, X.; Xiao, H.; Gong, D.; Yang, X.; Wu, F. *Tetrahedron* **2013**, *69*, 6993–7000.

(9) During the preparation of the manuscript, the Guillaumet group reported alkenylation reactions of indazoles. Naas, M.; El Kazouli, S.; Essassi, E. M.; Bousmina, M.; Guillaumet, G. *Org. Lett.* **2015**, *17*, 4320–4323.

(10) For dehydrogenative alkenylation at the arene ring of *N*-phenylpyrazole, see: (a) Umeda, N.; Hirano, K.; Satoh, T.; Miura, M. *J. Org. Chem.* **2009**, *74*, 7094–7099. (b) Arockiam, P. B.; Fischmeister, C.; Bruneau, C.; Dixneuf, P. H. *Green Chem.* **2011**, *13*, 3075–3078. (c) Hashimoto, Y.; Ueyama, T.; Fukutani, T.; Hirano, K.; Satoh, T.; Miura, M. *Chem. Lett.* **2011**, *40*, 1165–1166. For C–H alkylation at the arene ring of *N*-phenylpyrazole, see: (d) Ackermann, L.; Novák, P.; Vicente, R.; Hofmann, N. *Angew. Chem., Int. Ed.* **2009**, *48*, 6045–6048. (e) Ackermann, L.; Novák, P. *Org. Lett.* **2009**, *11*, 4966–4969. (f) Wang, H.; Schröder, N.; Glorius, F. *Angew. Chem., Int. Ed.* **2013**, *52*, 5386–5389.

(11) García-Rubia, A.; Urones, B.; Gómez Arrayás, R.; Carretero, J. C. *Chem.-Eur. J.* **2010**, *16*, 9676–9685.

(12) DFT calculations showed that solvent-ligated Pd complexes cleaved C–H bonds with lower barriers than those for phosphine-ligated ones. Tan, Y.; Hartwig, J. F. *J. Am. Chem. Soc.* **2011**, *133*, 3308–3311.

(13) For examples of biologically important alkenyl pyrazoles, see: (a) Rikimaru, K.; Wakabayashi, T.; Abe, H.; Imoto, H.; Maekawa, T.; Ujikawa, O.; Murase, K.; Matsuo, T.; Matsumoto, M.; Nomura, C.; Tsuge, H.; Arimura, N.; Kawakami, K.; Sakamoto, J.; Funami, M.; Mol, C. D.; Snell, G. P.; Bragstad, K. A.; Sang, B.-C.; Dougan, D. R.; Tanaka, T.; Katayama, N.; Horiguchi, Y.; Momose, Y. *Bioorg. Med. Chem.* **2012**, *20*, 714–733. (b) Sidique, S.; Shiryayev, S. A.; Ratnikov, B. I.; Herath, A.; Su, Y.; Strongin, A. Y.; Cosford, N. D. P. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5773–5777.

(14) Typically, fused pyrazole bicycles were synthesized by cyclocondensation with toxic hydrazine reagents. (a) Angelone, T.; Caruso, A.; Rochais, C.; Caputo, A. M.; Cerra, M. C.; Dallemagne, P.; Filice, E.; Genest, D.; Pasqua, T.; Puoci, F.; Saturnino, C.; Sinicropi, M. S.; El-Kashef, H. *Eur. J. Med. Chem.* **2015**, *92*, 672–681. (b) Bolea, C.; Celanire, S.; Liverton, N. J.; Yunfu, L. WO 2012/008999.

(c) Sparey, T.; Abeywickrema, P.; Almond, S.; Brandon, N.; Byrne, N.; Campbell, A.; Hutson, P. H.; Jacobson, M.; Jones, B.; Munshi, S.; Pascarella, D.; Pike, A.; Prasad, G. S.; Sachs, N.; Sakatis, M.; Sardana, V.; Venkatraman, S.; Young, M. B. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3386–3391. (d) Corbera, J.; Vaño, D.; Martínez, D.; Vela, J. M.; Zamanillo, D.; Dordal, A.; Andreu, F.; Hernandez, E.; Perez, R.; Escriche, M.; Salgado, L.; Yeste, S.; Serafini, M. T.; Pascual, R.; Alegre, J.; Calvet, M. C.; Cano, N.; Carro, M.; Buschmann, H.; Holenz, J. *ChemMedChem* **2006**, *1*, 140–154. (e) Kallman, N. J.; Liu, C.; Yates, M. H.; Linder, R. J.; Ruble, J. C.; Kogut, E. F.; Patterson, L. E.; Laird, D. L. T.; Hansen, M. M. *Org. Process Res. Dev.* **2014**, *18*, 501–510.

(15) Ye, M.; Gao, G.-L.; Yu, J.-Q. *J. Am. Chem. Soc.* **2011**, *133*, 6964–6967.

(16) (a) Zhang, S.; Shi, L.; Ding, Y. *J. Am. Chem. Soc.* **2011**, *133*, 20218–20229. (b) Cho, S. H.; Hwang, S. J.; Chang, S. *J. Am. Chem. Soc.* **2008**, *130*, 9254–9256.

(17) (a) Kubota, A.; Emmert, M. H.; Sanford, M. S. *Org. Lett.* **2012**, *14*, 1760–1763. (b) Cook, A. K.; Sanford, M. S. *J. Am. Chem. Soc.* **2015**, *137*, 3109–3118.

(18) We performed alkenylation reactions of butyl methacrylate using **7a** and **10a**, which also resulted in the formation of the corresponding isolated alkenes in 35% and 23% yields, respectively.

(19) Zeni, G.; Larock, R. C. *Chem. Rev.* **2006**, *106*, 4644–4680.

(20) For example, relatively electron-neutral pyrazole **14a** gave only a trace amount of the corresponding allylation product when it was subjected to the reactions conditions optimized for electron-deficient pyrazoles.

(21) Crystallographic data for the structures of **17b** and **19b** in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 1430928 and 1430927, respectively. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, U.K. (<http://www.ccdc.cam.ac.uk/>).

(22) (a) O'Connor, B.; Zhang, Y.; Negishi, E.-i.; Luo, F.-T.; Cheng, J.-W. *Tetrahedron Lett.* **1988**, *29*, 3903–3906. (b) Link, J. T. *The Intramolecular Heck Reaction. Organic Reactions*; John Wiley & Sons, Inc.: 2004; pp 157–534.

(23) Freeman, A. W.; Urvoy, M.; Criswell, M. E. *J. Org. Chem.* **2005**, *70*, 5014–5019.

(24) Grigg, R.; Kennewell, P.; Teasdale, A.; Sridharan, V. *Tetrahedron Lett.* **1993**, *34*, 153–156.

(25) Holzer, W.; Seiringer, G. *J. Heterocyclic Chem.* **1993**, *30*, 865–872.

(26) Taydakov, I. V.; Krasnoselskiy, S. S. *Synthesis* **2013**, *45*, 2188–2192.

(27) Zhao, Z.-G.; Wang, Z.-X. *Synth. Commun.* **2007**, *37*, 137–147.

(28) Dishington, A.; Feron, J. L.; Gill, K.; Graham, M. A.; Hollingsworth, I.; Pink, J. H.; Roberts, A.; Simpson, I.; Tatton, M. *Org. Lett.* **2014**, *16*, 6120–6123.

(29) Naas, M.; El Kazzouli, S.; Essassi, E. M.; Bousmina, M.; Guillaumet, G. *J. Org. Chem.* **2014**, *79*, 7286–7293.

(30) Sole, F. L.; Carranco, M. I.; Aiguade, B. J.; Puig, D. C.; Fonquerna, P. S. WO 2014/095920.